Cell Bio Human Tech Co.,Ltd (KOSDAQ:318160)
South Korea
· Delayed Price · Currency is KRW 4,625.00
+355.00 (8.31%)
At close: Mar 21, 2025, 3:30 PM KST
KOSDAQ:318160 Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2017 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2017 |
| Operating Revenue | 28,419 | 27,324 | 27,545 | 35,161 | 28,588 | Upgrade
|
| Other Revenue | -0 | - | - | - | - | Upgrade
|
| Revenue | 28,419 | 27,324 | 27,545 | 35,161 | 28,588 | Upgrade
|
| Revenue Growth (YoY) | 4.00% | -0.80% | -21.66% | 22.99% | 18.61% | Upgrade
|
| Cost of Revenue | 19,374 | 19,596 | 19,902 | 24,935 | 18,694 | Upgrade
|
| Gross Profit | 9,045 | 7,729 | 7,643 | 10,225 | 9,895 | Upgrade
|
| Selling, General & Admin | 4,099 | 3,268 | 3,000 | 3,212 | 3,834 | Upgrade
|
| Research & Development | 486.14 | 656.59 | 742.09 | 718.36 | 467.12 | Upgrade
|
| Other Operating Expenses | - | - | - | - | 52.77 | Upgrade
|
| Operating Expenses | 5,008 | 4,579 | 4,108 | 4,616 | 4,603 | Upgrade
|
| Operating Income | 4,037 | 3,149 | 3,535 | 5,610 | 5,292 | Upgrade
|
| Interest Expense | -411.21 | -489.03 | -454.76 | -611.9 | -20.02 | Upgrade
|
| Interest & Investment Income | 519.2 | 340.99 | 103.29 | 114.53 | 257.04 | Upgrade
|
| Earnings From Equity Investments | - | - | - | 30.18 | - | Upgrade
|
| Currency Exchange Gain (Loss) | 971.21 | -257.14 | 754.46 | 1,227 | -697.11 | Upgrade
|
| Other Non Operating Income (Expenses) | 57.39 | -2,975 | -377.89 | 11.75 | -65.47 | Upgrade
|
| EBT Excluding Unusual Items | 5,173 | -231.01 | 3,560 | 6,381 | 4,766 | Upgrade
|
| Gain (Loss) on Sale of Investments | 5 | - | - | -1,500 | 22.23 | Upgrade
|
| Gain (Loss) on Sale of Assets | 12.55 | -218.15 | -19.17 | -93.86 | 0.04 | Upgrade
|
| Asset Writedown | - | -362.66 | - | -308.07 | - | Upgrade
|
| Pretax Income | 5,191 | -811.82 | 3,541 | 4,479 | 4,789 | Upgrade
|
| Income Tax Expense | 812.16 | 1,045 | 650.94 | 1,367 | 573.2 | Upgrade
|
| Earnings From Continuing Operations | 4,379 | -1,857 | 2,890 | 3,113 | 4,215 | Upgrade
|
| Minority Interest in Earnings | - | - | - | 18.85 | -28.14 | Upgrade
|
| Net Income | 4,379 | -1,857 | 2,890 | 3,131 | 4,187 | Upgrade
|
| Preferred Dividends & Other Adjustments | - | - | - | - | 411.33 | Upgrade
|
| Net Income to Common | 4,379 | -1,857 | 2,890 | 3,131 | 3,776 | Upgrade
|
| Net Income Growth | - | - | -7.71% | -25.21% | -7.05% | Upgrade
|
| Shares Outstanding (Basic) | 9 | 8 | 7 | 7 | 7 | Upgrade
|
| Shares Outstanding (Diluted) | 9 | 8 | 7 | 8 | 8 | Upgrade
|
| Shares Change (YoY) | 5.65% | 20.57% | -11.32% | -1.95% | -1.05% | Upgrade
|
| EPS (Basic) | 491.00 | -220.00 | 412.78 | 447.27 | 527.47 | Upgrade
|
| EPS (Diluted) | 491.00 | -220.00 | 412.78 | 396.66 | 520.03 | Upgrade
|
| EPS Growth | - | - | 4.06% | -23.72% | 4.21% | Upgrade
|
| Free Cash Flow | 7,247 | 1,131 | 77.49 | 3,889 | -9,507 | Upgrade
|
| Free Cash Flow Per Share | 812.60 | 134.03 | 11.07 | 492.62 | -1180.77 | Upgrade
|
| Gross Margin | 31.83% | 28.29% | 27.75% | 29.08% | 34.61% | Upgrade
|
| Operating Margin | 14.21% | 11.53% | 12.83% | 15.96% | 18.51% | Upgrade
|
| Profit Margin | 15.41% | -6.80% | 10.49% | 8.91% | 13.21% | Upgrade
|
| Free Cash Flow Margin | 25.50% | 4.14% | 0.28% | 11.06% | -33.26% | Upgrade
|
| EBITDA | 5,943 | 4,953 | 5,396 | 7,149 | 6,443 | Upgrade
|
| EBITDA Margin | 20.91% | 18.13% | 19.59% | 20.33% | 22.54% | Upgrade
|
| D&A For EBITDA | 1,906 | 1,803 | 1,861 | 1,539 | 1,151 | Upgrade
|
| EBIT | 4,037 | 3,149 | 3,535 | 5,610 | 5,292 | Upgrade
|
| EBIT Margin | 14.21% | 11.53% | 12.83% | 15.96% | 18.51% | Upgrade
|
| Effective Tax Rate | 15.65% | - | 18.38% | 30.51% | 11.97% | Upgrade
|
| Advertising Expenses | - | - | - | 0.8 | 131.23 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.